Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

Inclusion Criteria: * Provision of signed and dated informed consent form. * Male or female, aged \>/= 18 years old * Life expectancy of greater than 3 months in the opinion of the investigator * Must have metastatic uveal melanoma, either initial presentation or recurrent, that is histologically diagnosed * Participant must have ECOG performance status of 0-1 * Participant must have measurable disease, according to RECIST version 1.1 * Participants must have normal organ and marrow function as defined below: * Leukocytes \>3,000/mcL * Absolute neutrophil count \>1,500/mcL * Platelets \>100,000/mcL * Total bilirubin within 1.5 x institutional upper limit of normal * AST(SGOT)/ALT(SGPT) \<2.5 X institutional upper limit of normal * Creatinine within 1.5 x institutional upper limit of normal OR creatinine clearance \>60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal * An echocardiogram should be performed at baseline in all patients. Ejection fraction (EF) from baseline echocardiogram must be within the institutional limits of normal as determined by the reading cardiologist. The left ventricular ejection fraction (LVEF) must be ≥50% * Participants on full-dose anticoagulants (e.g., warfarin) with PT INR \>1.5 are eligible provided that both of the following criteria are met: * a) The participant has an in-range INR (usually between 2 and 3) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin * b) The pa…